Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System

Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System

Item

http://www.wikidata.org/entity/Q28261953

Q28261953

about

The role of urotensin II in cardiovascular and renal physiology and diseases Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer.GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803)The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems Potential Clinical Implications of the Urotensin II Receptor Antagonists.Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation Population pharmacodynamic modeling of hyperglycemic clamp and meal tolerance tests in patients with type 2 diabetes mellitus.Urotensin II in cardiovascular regulation.Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.Role of urotensin II in health and disease.Emerging drugs for managing kidney disease in patients with diabetes.Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension.Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction.Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.Update on the urotensinergic system: new trends in receptor localization, activation, and drug design Prediction of the three-dimensional structure for the rat urotensin II receptor, and comparison of the antagonist binding sites and binding selectivity between human and rat receptors from atomistic simulations.The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation.Urotensin-II contributes to pulmonary vasoconstriction in a perinatal model of persistent pulmonary hypertension of the newborn secondary to meconium aspiration syndrome.Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects.Predicted ligands for the human urotensin-II G protein-coupled receptor with some experimental validation.Renal effects of human urotensin-II in rats with experimental congestive heart failure.Potent cardiovascular effects of homologous urotensin II (UII)-related peptide and UII in unanesthetized eels after peripheral and central injections.Can early myocardial infarction-related deaths be diagnosed using postmortem urotensin receptor expression levels?

P2860

Q24675590-6C3BD7D4-AE1B-4B62-8D02-4C466752AC98 Q28260943-2257BED9-82A1-4198-8176-876079A468A4 Q30486707-3A621D92-B41D-4787-B993-E938B960F64A Q34066190-BE39B981-D2FF-47A1-9559-ACE551B919EB Q34233981-5BA546A6-5633-4C39-9F92-6157597E545D Q34260110-461AF06D-BA1A-463E-8BF8-93C00A6C2B84 Q35098581-94D14E93-21B6-4487-9D47-5BFD4C809C86 Q35100902-883364D8-E628-4408-B33A-0762FFBCCF04 Q35128456-A3CDB9EE-5F12-43CA-875B-291BD4D368B8 Q35545386-B11F2CDE-46DA-4D96-B70A-75C5D6F4B2CB Q37207848-1A72E44E-0CAE-4B28-BBB5-02B0BC9A9B5A Q37344439-FFD2C5A2-B2CE-4B18-BDF7-A20D1BA7E19C Q37427914-2D830F90-147D-4A7D-8E0B-3E2C06284656 Q37737495-10D7473E-473B-4A6D-8C45-B3D217DBEEDE Q38075029-2D462672-1642-49A2-B343-EFC40DD8F41F Q38093584-398D1F8E-183D-4FA2-881C-D3B0F2C2732E Q39236752-E0843CCB-48F6-46D9-BE8A-F57FDDE789D7 Q39939179-C42DFCA5-52DD-4D40-85CF-A50A03D3C15A Q39967100-49DEFB5D-A626-4DE2-A9D6-9371F1849792 Q40430686-8F41206F-DC90-435F-BECF-F9907465028E Q41767436-0F8B2FD2-94FC-45BF-BFAE-281A1549A1EA Q42397196-3183967D-884B-4236-96BC-7C56A9EB34C1 Q43146165-B49EDC18-0DD7-4290-B0EE-E0D06007794A Q43266046-0F1D2672-63B5-4BA2-9CCF-DC6625511CD8 Q45922685-3429E5DE-90B8-4931-B85E-D06B23769F64 Q46248274-D47FECB8-6FAF-4C9E-9D4B-9FB3D381BFC7 Q46882457-EC9296A2-D549-4EC6-99E8-3C5D805624C3 Q48061365-B37350C0-25B4-4180-A0B6-CF15162667A8 Q54202541-A2173B89-89A5-40E3-8D15-FE90F3ACB2DE

P2860

Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System

Item

http://www.wikidata.org/entity/Q28261953

description

2004 nî lūn-bûn

@nan

2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue